cepi and sk bioscience extend collaboration to develop first generation covid-19 vaccine
cepi and sk bioscience extend collaboration to develop first generation covid-19 vaccine
cepi has also partnered with bioscience facilities sk bioscience and gc pharma to reserve manufacturing capacities exclusively for one or more cepi-funded covid-19 vaccines.", "im pleased to expand our partnership with sk bioscience to develop their vaccine candidate, gbp510, which marks cepis first investment in wave 2 vaccines.", "for the covid-19 vaccine response, sk bioscience is undergoing development for its vaccine candidate against sars- cov-2 with support from the bill and melinda gates foundation and cepi, and using its established development and manufacturing capabilities, it has recently agreed to develop and manufacture astrazenecas and novavaxs covid-19 vaccine candidates.", 


































"sk bioscience and cepi are committed to global equitable access of covid-19 vaccines and have agreed that this vaccine candidate will be made available for procurement and allocation, if proven to be safe and effective, through the covid-19 vaccine global access (covax) facility.")